摘要
Abstract
Objective:To investigate the effect of Salmeterol Fluticasone(SFC)combined with Montelukast Sodium(MK)on bronchial asthma(BA).Methods:A total of 78 BA patients admitted to Shouguang People's Hospital from January 2022 to December 2023 were selected as the study objects and were divided into a control group and a study group according to random number table method,with 39 cases in each group.The control group was treated with SFC,and the study group was treated with MK based on the control group.Both groups were treated 3 months.The levels of inflammatory factors,lung function and occurrence of adverse reactions were compared between the two groups.Results:After treatment,the levels of hypersensitive C-reactive protein,interleukin-4 and interleukin-5 in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the forced expiratory volume in one second,forced vital capacity and one-second rate of the study group were higher than those of the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 12.82%,which was higher than 5.13%in the control group,but there was no statistical significance(P>0.05).Conclusion:Compared with SFC alone,SFC combined with MK in the treatment of BA can more effectively reduce the level of serum inflammatory factors and improve the respiratory function of patients with good safety.关键词
支气管哮喘/沙美特罗替卡松/孟鲁司特钠/炎性因子/呼吸功能Key words
Bronchial asthma/Salmeterol and fluticasone/Montelukast sodium/Inflammatory factor/Lung function分类
临床医学
